US 11,965,040 B2
Modulation of complement activity
Michelle Denise Hoarty, Billerica, MA (US); Ketki Ashok Dhamnaskar, Foster City, CA (US); Daniel Elbaum, Newton, MA (US); Kristopher Josephson, San Carlos, CA (US); Kelley Cronin Larson, Quincy, MA (US); Zhong Ma, Lexington, MA (US); Nathan Ezekiel Nims, Winchester, MA (US); Alonso Ricardo, Winchester, MA (US); Kathleen Seyb, Wakefield, MA (US); Guo-Qing Tang, Acton, MA (US); Douglas A. Treco, Arlington, MA (US); Zhaolin Wang, Wellesley, MA (US); Ping Ye, Lexington, MA (US); Hong Zheng, New York, NY (US); Sarah Jacqueline Perlmutter, Urbana, IL (US); and Robert Paul Hammer, Maynard, MA (US)
Assigned to RA PHARMACEUTICALS, INC., Cambridge, MA (US)
Filed by Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 21, 2021, as Appl. No. 17/236,247.
Application 17/236,247 is a continuation of application No. 16/732,502, filed on Jan. 2, 2020, granted, now 11,014,965.
Application 16/732,502 is a continuation of application No. 16/554,665, filed on Aug. 29, 2019, granted, now 10,562,934, issued on Feb. 18, 2020.
Application 16/554,665 is a continuation of application No. 16/237,893, filed on Jan. 2, 2019, granted, now 10,435,438, issued on Oct. 8, 2019.
Application 16/237,893 is a continuation of application No. 16/128,561, filed on Sep. 12, 2018, granted, now 10,208,089, issued on Feb. 19, 2019.
Application 16/128,561 is a continuation of application No. 15/318,063, granted, now 10,106,579, issued on Oct. 23, 2018, previously published as PCT/US2015/035473, filed on Jun. 12, 2015.
Claims priority of provisional application 62/108,772, filed on Jan. 28, 2015.
Claims priority of provisional application 62/077,460, filed on Nov. 10, 2014.
Claims priority of provisional application 62/011,368, filed on Jun. 12, 2014.
Prior Publication US 2021/0246167 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 47/64 (2017.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 47/64 (2017.08); A61K 47/645 (2017.08); C07K 7/06 (2013.01); C07K 16/00 (2013.01); A61K 38/00 (2013.01)] 12 Claims
 
1. A pharmaceutical composition comprising:
a polypeptide that binds complement component C5, the polypeptide comprising the formula R1-Tyr-Xaa0-Glu-Tyr-R2, wherein:
R1 comprises a polypeptide;
Xaa0 is selected from the group consisting of Trp, azaTrp, N-methyl Trp, 1-methyl Trp, and 3-aminomethyl Phe; and
R2 comprises a polypeptide;
a pharmaceutically acceptable carrier or excipient.